Total Therapy GIMEMA LAL 1509 Protocol for De Novo Adult Ph+ ALL Patients: Updated Results and Genetic-Based Prognostic Stratification
Preliminary findings of the GIMEMA LAL 1509 total therapy protocol, which evaluated the tyrosine kinase inhibitor dasatinib plus steroids as induction therapy in adult patients with de novo Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) were presented previously.1 At ASH [ Read More ]